Which cardiac parameters best predict the cardiovascular outcomes among patients with anti-PD-1 immunotherapy-induced myocardial injury?

Xiongjun Peng¹, Yawen Zheng², Zhaowei Zhu³, Na Liu¹, Shenghua Zhou³ and Junke Long⁴*

¹The Second Xiangya Hospital, Central South University, Changsha, China, ²National Clinical Research Center for Geriatric Disorders, Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, China, ³Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, China

Aim: To explore the association of cardiac parameters with different clinical outcomes in patients with anti-PD-1 immunotherapy-induced myocardial injury.

Methods and results: We screened 3,848 patients who received anti-PD-1 immunotherapy from June 2018 to October 2021 at the Second Xiangya Hospital of Central South University. Among those patients, 134 patients were diagnosed with anti-PD-1 immunotherapy-induced myocardial injury. Twenty-four patients with cardiovascular symptoms were divided into the major adverse cardiovascular events (MACE) group, and 110 patients without cardiovascular symptoms were divided into the non-MACE group. We compared creatine kinase isozyme (CK-MB), high-sensitivity troponin T (hsTNT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), electrocardiography (ECG), and echocardiographic parameters between the two groups of patients. CK-MB, hsTNT, NT-proBNP [2,600.0 (1,317.00–7,950.00) vs. 472.9 (280.40–788.80), p ≤ 0.001], left ventricular end-diastolic diameter (LVEDd), left ventricular ejection fraction (LVEF) and QRS interval were significantly different. The receiver operating characteristic (ROC) curve was used to compare the accuracy of various indicators to predict the occurrence of MACE events. NT-proBNP (area under the curve [AUC] 97.1) was the best predictor, followed by CK-MB (AUC = 94.1), LVEF (AUC = 83.4), LVEDd (AUC = 81.5), and other indicators. In the MACE group, 11/24 patients had experienced cardiogenic death by the end of follow-up. There were significant differences in the CK-MB, hsTNT, NT-proBNP, LVEDd, LVEF, and QRS intervals between the deceased patients and the survivors. The ROC curve shows that hsTNT is the most accurate marker for predicting cardiogenic death in the MACE group (AUC = 91.6).

Conclusion: In patients with myocardial injury after PD-1 inhibitor treatment, NT-proBNP is the parameter of choice to predict the likelihood of developing cardiovascular symptoms, whereas, in symptomatic patients, hsTNT is the

OPEN ACCESS

EDITED BY
Dong Han,
People’s Liberation Army General Hospital, China

REVIEWED BY
Zaza Iakobishvili,
Tel Aviv University, Israel
Alessandra Cuomo,
Federico II University Hospital, Italy

*CORRESPONDENCE
Junke Long
drburkes@cniu.edu.cn

SPECIALTY SECTION
This article was submitted to Cardio-Oncology, a section of the journal Frontiers in Cardiovascular Medicine

RECEIVED 17 April 2022
ACCEPTED 22 August 2022
PUBLISHED 23 September 2022

COPYRIGHT © 2022 Peng, Zheng, Zhu, Liu, Zhou and Long. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Introduction

Cancer and cardiovascular diseases are the two most important categories of diseases affecting human health (1). Immunotherapy has advanced rapidly in the treatment of tumors in recent decades (2). In particular, immune checkpoint inhibitors (ICIs) represented by anti-programmed cell death-1 (PD-1) antibody therapy are one of the most commonly used immunotherapy methods worldwide (3). According to the guidelines published by multiple oncology organizations around the world (4, 5), PD-1 inhibitors have become a standard treatment for a variety of solid advanced malignancies, and immunotherapy-induced myocardial injury has increasingly been recognized with the widespread use of these agents (6). Some patients have only isolated elevation of serum markers of myocardial injury without any complaints, such as creatine kinase isozyme (CK-MB), high-sensitivity troponin T (hsTnT), and N-terminal pro-B-type natriuretic peptide (NT-proBNP). However, some patients treated with anti-PD-1 inhibitors also have severe cardiovascular manifestations, such as heart failure (HF), malignant arrhythmias, and death, even though a lower incidence of 0.3–2% has been reported in the literature (7, 8). The mechanism leading to this completely different clinical outcome is not yet been fully understood and may be related to the excessive activation of inflammation. In addition, whether patients with asymptomatic myocardial injury need treatment is unclear. Regardless, it is foreseeable that the use of ICIs will continue to increase as the cost decreases, and therefore, how to accurately identify the severity of PD-1 inhibitor-induced myocardial injury at an early stage is of great importance but remains unclear.

Our objective was to identify the association of cardiac parameters with different clinical outcomes in patients with anti-PD-1 immunotherapy-induced myocardial injury and find a better cardiac parameter to predict these outcomes of different severities.

Patients and methods

Patients

This is a retrospective cohort study, we screened 3,848 patients who received anti-PD-1 immunotherapy from June 2018 to Oct 2021 at the Second Xiangya Hospital of Central South University. Among those patients, 134 patients were diagnosed with anti-PD-1 immunotherapy-induced myocardial injury. These patients were from the Department of Oncology, Department of Respiratory Medicine, Department of Cardiology, Department of Thoracic Surgery, Department of Critical Medicine, and Department of Emergency. Medical records are from the inpatient, outpatient, and emergency medical systems. Data including demographic characteristics, comorbidities, main complaint at diagnosis, laboratory testing results, electrocardiography (ECG), echocardiographic findings, and treatment were obtained. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki (9) as reflected by prior approval from the human research committee of the Second Xiangya Hospital of Central South University. Written informed consent was obtained from patients while the patient was in a clinically stable, non-congested condition or from their family members who could give informed consent on behalf of patients after they were informed about the objectives and procedures of the study. Their rights to refuse participation any time they wanted were assured. For this purpose, a one-page consent letter was attached as a cover page of each questionnaire stating the general objective of the study and issues of confidentiality that were discussed by the data collectors before proceeding with the data collection.

Diagnostic procedures

A total of 3,848 patients who received PD-1 antibody therapy were evaluated. The inclusion criteria were as follows: (1) High-sensitivity troponin T was negative in patients before PD-1 antibody treatment, but the concentration increased in patients after treatment. The exclusion criteria were: (1) Acute or suspected renal function injury leading to false elevation of high-sensitivity troponin T levels; and (2) Use of other drugs that may cause myocardial injuries, such as anthracycline chemotherapeutic drugs, cyclophosphamide, and trastuzumab. Finally, 134 patients were included in the study (see flowchart in Figure 1 for details).
Data collection

Demographic and clinical characteristics were collected when the diagnosis of PD-1 inhibitor-induced myocardial injury was confirmed. Blood test parameters, ECG, and cardiac ultrasound parameters were the first reports obtained after diagnosis. Patient-reported comorbidities were listed according to what the patient told our doctor on admission and what we diagnosed after discharge. The tracking of hsTNT and NT-proBNP is generally divided into two situations. The first is that it is detected in our hospital when symptoms appear. The second is the routine detection of asymptomatic patients on admission for anti-tumor treatment. High-sensitivity troponin T (hsTnT) was measured by electrochemiluminescence (Roche, Germany). The upper limit of the reference value (99th quantile) in the manual is 14 pg/ml.

Definitions and outcome

The outcome of interest, major adverse cardiac events (MACE), was a composite of cardiovascular death, cardiac arrest, HF, and arrhythmias that cause hemodynamic abnormalities such as tachyarrhythmias/bradyarrhythmias and acute myocardial infarction (AMI). For cases where cardiac arrest, HF, arrhythmias, and AMI led to death, the outcome was counted as cardiac death. Standard definitions were used for cardiovascular death, cardiac arrest, HF, and AMI (10, 11). Survival time (days) was measured as the duration between the first day of hospitalization when the patient received PD-1 antibody therapy to the date of MACE or death from any cause. Data were obtained from medical records or from telephone interviews with patients or relatives by 2 trained physicians. We chose to set the follow-up time to 90 days because previous clinical studies showed that the vast majority of cardiotoxicity occurred within 90 days following the use of PD-1 inhibitors (12). Patients were followed until 16 October 2021. Patients were censored if they were still alive at the end of the research period or were lost to follow-up, on which occasion their last clinic visit or correspondence time was used.

Statistical analysis

Normally distributed parameters are expressed as the mean ± standard deviation (SD), whereas non-normally distributed parameters are expressed as the median with interquartile range (IQR). Categorical values are presented as numbers.
Cardiovascular Medicine

Results

Patient characteristics

In the MACE group, 16 patients had a new onset HF, 3 patients had non-ST segment elevation myocardial infarction (NSTEMI), 3 patients had new-onset symptomatic arrhythmia, and 1 patient had a sudden cardiac arrest. In the non-MACE group, 3 patients had new-onset symptomatic arrhythmia, independent groups was performed using an unpaired Student’s t-test (if normally distributed) or Mann–Whitney U test (non-normally distributed variables), and in cases where more than two groups were compared, one-way analysis of variance (ANOVA) or the Kruskal–Wallis test was used. Univariate analyses were performed to examine the correlates between cardiac parameters and different outcomes using the logistic regression models. The receiver operating characteristic (ROC) curve was used to reflect the accuracy of different cardiac parameters in predicting different outcomes by the area under the curve (AUC). Survival was evaluated with Kaplan–Meier curves. All tests were two-tailed and a p-value of < 0.05 was considered to indicate statistically significant. Statistical analysis was performed using SPSS 26.0 (IBM Software Inc), EmpowerStats 3.0 software, and R (version 3.3.2).

Cancer characteristics of interest

The time from the first day of PD-1 inhibitor treatment to the date when PD-1 inhibitor-induced myocardial injury diagnosis was confirmed was 37.04 ± 20.26 days for the MACE group and 32.85 ± 17.97 days for the non-MACE group. Regarding the tumor proportion scores (TPS) of PD-1 expression by tumor tissue immunohistochemistry, there was no difference between the two groups (47.35 ± 27.51 vs. 44.12 ± 27.23, p = 0.654). Regarding the anti-tumor regimen, 7 (29.2%) patients in the MACE group and 40 (36.4%) patients in the non-MACE group received PD-1 inhibitor monotherapy. The remaining cases were treated with chemotherapy combined with immunotherapy. More than half of the patients' primary tumors were non-small-cell lung cancer (NSCLC), followed by esophageal cancer, liver cancer, and other tumors (details in Table 1).

Cardiac parameters among subjects

In the MACE group, CK-MB (108.97 ± 57.09 vs. 31.86 ± 43.66, p ≤ 0.001), hsTNT [195.5 (108.75–302.50) vs. 78.00 (47.85–124.00), p ≤ 0.001], and NT-proBNP [2,600.0 (1,317.00–7,950.00) vs. 472.9 (280.40–788.80), p ≤ 0.001] levels were significantly higher than those in the non-MACE group. Regarding the parameters of echocardiography, in the MACE group, patients had a higher left ventricular end-diastolic diameter (LVEDd) (51.5 ± 6.1 vs. 43.5 ± 6.2, p ≤ 0.001) and lower left ventricular ejection fraction (LVEF) (46.7 ± 9.1 vs. 57.2 ± 7.5, p ≤ 0.001) than those in the non-MACE group. There were no significant differences in other cardiac parameters between the two groups (Table 2). The ECG parameters between the two groups were also somewhat different. The incidence of bradycardia and tachycardia in the MACE group was higher than that in the non-MACE. The QRS interval of the MACE group was significantly wider than that of the non-MACE group (127.2 ± 33.5 vs. 93.7 ± 16.1, p = 0.001), but the corrected QT interval of the two groups was no different (details in Table 2).

Outcome of all cases

The median follow-up of all cases was 90 days (12–102 days). In the MACE group, 13/24 of patients survived after careful treatment. The number of all-cause deaths in the MACE group was 12 (50%) as the end of follow-up, and one of them was non-cardiogenic death (lungs infection). For the non-MACE group, 16/110 (14.5%) of patients had non-cardiogenic deaths, and the rest were still alive at the end of follow-up. The K–M survival curves of the two groups are shown in Figure 2.

Cardiac parameters among survivors and deceased patients in the MACE group

In the MACE group, 13/24 of patients survived after treatment, and 11/24 died after treatment. Compared with those of the survivors, the CK-MB (146.4 ± 56.2 vs. 77.3 ± 35.3, p ≤ 0.001), hsTNT [300.0 (218.5–729.0) vs. 112.0 (84.0–122.0), p ≤ 0.001], and NT-proBNP [8,400.0 (3,850.0–14,000.0) vs. 1,890.0 (1,200.0–2,400.0), p ≤ 0.001] levels of the deceased...
TABLE 1 Characteristics of 134 patients with programmed cell death (PD-1)-related myocardial injury.

|                          | No MACE (n = 110) | MACE (n = 24) | P-value |
|--------------------------|-------------------|---------------|---------|
| Age, years               | 60.4 (9.9)        | 66.5 (8.1)    | 0.010   |
| Male, n (%)              | 86(78.2)          | 18 (75)       | 0.735   |
| SBP, mmHg                | 115.48 (21.13)    | 119.25 (17.52)| 0.233   |
| DBP, mmHg                | 70.45 (11.57)     | 70.46 (13.47)| 0.738   |
| NYHA, n (%)              | 110(100)          | 9(37.5)       | < 0.001 |
| Class I–II               | 15(62.5)          |               |         |
| SpO2, %                  | 96.45 (2.43)      | 96.25 (2.72)  | 0.962   |
| TPS, %                   | 47.35 (27.51)     | 44.12 (27.23)| 0.654   |
| Days from first dose     | 32.85 (17.97)     | 37.04 (20.26)| 0.257   |
| Primary cancer type, n (%)|                   |               |         |
| Lung cancer              | 66 (60)           | 16 (66.7)     |         |
| Esophageal cancer        | 14 (12.7)         | 2 (8.3)       |         |
| Liver cancer             | 10 (9.1)          | 3 (12.5)      |         |
| Other tumors             | 20 (18.2)         | 3 (12.5)      |         |
| Comorbidities, n (%)     |                   |               | 0.356   |
| COPD                     | 15 (13.6)         | 5 (20.8)      |         |
| Hypertension             | 38 (34.5)         | 8 (33.3)      |         |
| Hyperlipidemia           | 28 (25.5)         | 6 (25)        |         |
| CKD                      | 22 (20)           | 5 (20.8)      |         |
| T2DM                     | 16 (14.6)         | 2 (8.4)       |         |
| Stroke                   | 15 (13.6)         | 2 (8.3)       |         |
| CHD                      | 16 (14.5)         | 6 (25)        |         |
| Anti-tumor regimen, n (%)|                   |               | 0.188   |
| PD-1 monotherapy         | 40 (36.4)         | 7 (29.2)      |         |
| Combined chemotherapy    | 70 (63.6)         | 17 (70.8)     |         |
| Concurrent side effects, n (%)|               |               | 0.001   |
| Pneumonitis              | 1 (0.9)           | 7 (29.2)      |         |
| Hepatitis                | 3 (2.7)           | 3 (12.5)      |         |
| Thyroid dysfunction      | 16 (14.5)         | 5 (20.8)      |         |
| Myositis                 | 3 (2.7)           | 4 (16.7)      |         |
| Baseline cardiac parameters|                         |               |         |
| Cardiac troponin T, pg/mL| 8.0 (6.3–10.2)    | 7.6 (5.3–9.8) | 0.285   |
| PR interval, ms          | 154.9 ± 17.3      | 161.2 ± 36.4  | 0.214   |
| Corrected QT interval, ms| 452.6 ± 36.2      | 448.5 ± 52.2  | 0.654   |
| QRS duration, ms         | 95.2 ± 19.4       | 87.0 ± 17.1   | 0.058   |
| Baseline cardiovascular medications|               |               |         |
| Aspirin                  | 15 (13.6%)        | 5 (20.8%)     | 0.370   |
| ACEI or ARB              | 10 (9.1%)         | 4 (16.7%)     | 0.272   |
| β-blockers               | 11 (10.0%)        | 4 (16.7%)     | 0.348   |

Data are (N) Mean (SD) or (N) n (%), Median (Q3–Q1), where N is the total number of patients with available data. SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; SpO2, Saturation of Peripheral Oxygen; TPS, Tumor Proportion Score; NYHA, New York Heart Association Functional Classification; CHD, Coronary Heart Disease; COPD, Chronic Obstructive Pulmonary Disease; CKD, Chronic Kidney Disease; T2DM, Type 2 Diabetes Mellitus; PD-1, Programmed Cell Death.

patients were significantly higher. Regarding the parameters of echocardiography, deceased patients had higher LVEDd (54.7 ± 4.7 vs. 48.7 ± 5.8, p ≤ 0.009) and lower LVEF (39.7 ± 6.4 vs. 52.6 ± 6.5, p ≤ 0.001) than those survivors. The QRS interval of the deceased patient group was significantly longer than that of the survivor groups (144.0 ± 37.5 vs. 113.1 ± 20.5, p = 0.020). There were no significant differences in other cardiac parameters between the two groups (Table 3).
The association between cardiac parameters and different outcomes

Univariate logistic regression was used to analyze the association between cardiac parameters and different outcomes. Age (OR = 1.08, 95% CI = 1.02–1.14, p = 0.007), CK-MB (OR = 1.03, 95% CI = 1.01–1.04, p < 0.001), hsTNT (OR = 1.01, 95% CI = 1.01–1.01, p = 0.001), NT-proBNP (OR = 1.0, 95% CI = 1.0–1.1, p < 0.001), LVEDd (OR = 1.21, 95% CI = 1.12–1.32, p < 0.001), LVEF (OR = 0.87, 95% CI = 0.82–0.93, p < 0.001), and QRS interval (OR = 1.04, 95% CI = 1.02–1.06, p < 0.001) were predictive of the development of cardiovascular symptoms (MACE events) in patients with PD-1 inhibitor-induced myocardial injury. The ROC curve was used to compare the accuracy of various indicators to predict the occurrence of MACE events. NT-ProBNP (AUC = 97.1) was the best predictor, followed by CK-MB (AUC = 94.1), LVEF (AUC = 83.4), LVEDd (AUC = 81.5), and other indicators, as shown in Figure 3A. In the MACE group, CK-MB (OR = 1.04, 95% CI = 1.01–1.07, p < 0.021), NT-proBNP (OR = 1.0, 95% CI = 1–1, p < 0.042), hsTNT (OR = 1.02, 95% CI = 1–1.04, p < 0.034), and QRS duration (OR = 1.04, 95% CI = 1–1.07, p < 0.032) were predictors of death. The ROC curve revealed that hsTNT was the most accurate predictive marker (AUC = 91.6; more details in Table 4 and Figure 3B).

Discussion

This is a retrospective case analysis from a large referral hospital. We are deeply concerned about the increase in high-sensitivity troponin T levels after PD-1 inhibitor treatment, and previous studies have reported that the incidence is very low. In the safety study of more than 2,000 patients with immunotherapy released by Bristol–Myers Squibb, the rate of myocarditis in patients treated with ipilimumab or nivolumab...
was 0.09%. Among patients receiving combination therapy, the incidence of myocarditis is approximately 0.3%, and its severity is greater than that of patients receiving monotherapy (8). A retrospective case study of PD-1 inhibitor treatment reported that the prevalence of myocarditis was 1.14% with a median time of onset of 34 days after starting PD-1 inhibitor treatment (IQR: 21–75 days) (13). Since many patients do not routinely have ECG and markers of myocardial injury monitored, some studies suggest or believe that the proportion of myocarditis caused by PD-1 inhibitors may be higher than 1% (7). However, in clinical practice, we often encounter patients who show only elevated levels of cardiac troponin, a marker of myocardial injury but have no symptoms after treatment with PD-1 inhibitors. These patients have not been well evaluated. Our study showed that 3.48% (134/3848) of patients had increased high-sensitivity troponin T levels after PD-1 inhibitor monotherapy. This ratio is very high and still underestimated because some patients without cardiovascular symptoms have not been monitored for troponin levels. Our study indicated that 24 patients (0.62%) had cardiovascular symptoms, and 11 of them suffered cardiogenic death. If these symptomatic patients are defined as having myocarditis, this is equivalent to the incidence rate of previous studies.

Our study supports the need for routine monitoring of cardiac parameters in patients using PD-1 inhibitors. Oncologists in many countries currently recommend routine detection of myocardial injury markers, such as CK-MB, CK, troponin, and BNT-proBNP, during each cycle of PD-1 inhibitors (14, 15). However, the importance of the elevated levels of each marker is unclear, and cardiovascular physicians often go to the oncology department for consultation. Our study indicates that the higher the increase in these cardiac parameters, the worse the prognosis. Therefore, routine monitoring of cardiac parameters should be performed in patients receiving PD-1 inhibitors.
TABLE 3 Cardiac parameters among survivors and deceased patients.

|                          | Survived (N = 13) | Deceased (N = 11) | P-value |
|--------------------------|-------------------|-------------------|---------|
| Age, years               | 63.8 (7.7)        | 69.6 (7.6)        | 0.124   |
| Male, n (%)              | 11 (84.6%)        | 7 (63.6%)         | 0.357   |
| **Cardiovascular manifestations** |                 |                   |         |
| Dyspnea                  | 8 (61.5%)         | 9 (81.8%)         | 0.386   |
| Edema                    | 2 (15.4%)         | 2 (18.2%)         | 0.855   |
| Palpitation              | 3 (23.1%)         | 0 (0.0%)          | 0.233   |
| Chest pain               | 4 (30.8%)         | 1 (9.1%)          | 0.327   |
| Days from first dose to onset | 36.7 (20.4)     | 37.5 (21.0)       | 0.772   |
| **Cardiac parameters**   |                   |                   |         |
| SBP, mmHg                | 124.5 (17.3)      | 113.1 (16.5)      | 0.111   |
| DBP, mmHg                | 74.6 (10.2)       | 65.5 (15.6)       | 0.147   |
| CK-MB, u/L               | 77.3 (35.3)       | 146.4 (56.2)      | 0.003   |
| Cardiac troponin T, pg/mL| 112.0 (84.0–122.0)| 300.0 (218.5–729.0)| 0.001   |
| NT-proBNP, pg/mL         | 1,890.0           | 8,400.0           | 0.002   |
| (1,200.0–2,400.0)        | (3,850.0–14,000.0)|                  |         |
| **Echocardiographic findings** |             |                   |         |
| LVEDd, mm                | 48.7 (5.8)        | 54.7 (4.7)        | 0.009   |
| RVEDd, mm                | 32.1 (3.7)        | 34.2 (5.0)        | 0.222   |
| LAEdd, mm                | 35.9 (6.1)        | 39.1 (2.5)        | 0.130   |
| RAEdd, mm                | 32.9 (5.9)        | 34.1 (4.2)        | 0.662   |
| LVEF, (%)                | 52.6 (6.5)        | 39.7 (6.4)        | <0.001  |
| **ECG findings**         |                   |                   |         |
| Atrial fibrillation, n (%)| 0 (0.0%)          | 1 (9.1%)          | 0.458   |
| Advanced AV block, n (%) | 3 (23.1%)         | 5 (45.5%)         | 0.390   |
| Bundle branch block      | 2 (15.4%)         | 5 (45.5%)         | 0.182   |
| FVP or VT, n (%)         | 4 (30.8%)         | 7 (63.6%)         | 0.107   |
| PR interval, ms          | 173.9 (28.2)      | 161.7 (23.0)      | 0.234   |
| Corrected QT interval, ms| 471.2 (40.9)      | 469.7 (29.7)      | 0.977   |
| QRS duration, ms         | 113.1 (20.5)      | 144.0 (37.5)      | 0.020   |

Data are (N) Mean (SD) or (N) n (%), Median (Q3–Q1), where N is the total number of patients with available data. For other abbreviations, see Table 2.

markers levels, the greater the probability of occurrence of cardiac symptoms. In addition, our study indicates that the QRS interval on ECG is also a clinical indicator for predicting whether patients will have symptoms, which suggests that ECG is also very important in monitoring patients for adverse drug reactions. This is similar to a previous study by Zlotoff et al., which showed that the QRS duration is increased in ICI myocarditis and is associated with increased MACE risk, especially in patients whose QRS interval is greater than 110 ms (16). We think this is mainly related to the occurrence of more ventricular arrhythmias in the MACE group. With an increasing number of ventricular arrhythmias, the probability of cardiovascular symptoms will obviously increase. Of course, cardiac ultrasound is a very accurate tool to judge whether a patient has cardiac dysfunction, especially the LVEF is a very important indicator. However, using the ROC curve for comparison, NT-proBNP is the best cardiac parameter predicting clinical symptoms in patients with PD-1 inhibitor-mediated myocardial injury. This may be related to the fact that most patients in the MACE group present with symptoms of HF.

Our study indicated that the most common occurrence of cardiovascular system symptoms after PD-1 inhibitor treatment is HF symptoms, manifested as dyspnea and edema. Then, five patients presented with chest pain, four patients experienced palpitations, and one patient died suddenly after elevated troponin levels were observed. Notably, 62.5% (16/24) of patients in the MACE group entered the intensive care unit for treatment. However, 45.8% (11/24) of the patients eventually experienced cardiogenic death. Such a high mortality rate is similar to that reported in Western countries (17–19). Additionally, the proportion of corticosteroid treatment was
TABLE 4 Logistic regression analysis of the association between cardiac parameters and different outcomes.

| Variables       | MACE among 124 patients | p-value |
|-----------------|--------------------------|---------|
|                 | OR (95% CI)              |         |
| Age             | 1.08 (1.02~1.14)         | 0.007   |
| Male            | 1.19 (0.43~3.34)         | 0.735   |
| CK-MB           | 1.03 (1.01~1.04)         | <0.001  |
| Cardiac troponin T | 1.01 (1~1.01)       | 0.001   |
| NT-proBNP       | 1.0 (1.00~1)             | <0.001  |
| LVEDd, mm       | 1.21 (1.12~1.32)         | <0.001  |
| RVEDd, mm       | 0.97 (0.87~1.07)         | 0.515   |
| LAESd, mm       | 1.03 (0.95~1.11)         | 0.505   |
| RAESd, mm       | 0.98 (0.89~1.06)         | 0.569   |
| LVEF            | 0.87 (0.82~0.93)         | <0.001  |
| PR interval     | 1 (0.98~1.01)            | 0.75    |
| Corrected QT interval | 1.01 (1~1.02)     | 0.093   |
| QRS duration    | 1.04 (1.02~1.06)         | <0.001  |

Cardiac death among 24 patients

| Variables      | OR (95% CI) | p-value |
|----------------|-------------|---------|
| Age            | 1.11(0.99~1.25) | 0.086   |
| Male           | 3.14 (0.45~21.96) | 0.248   |
| CK-MB          | 1.04 (1.01~1.07) | 0.021   |
| Cardiac troponin T | 1.02 (1~1.04)  | 0.034   |
| NT-proBNP      | 1 (1~1)      | 0.042   |
| LVEDd, mm      | 0.87 (0.7~1.07) | 0.184   |
| RVEDd, mm      | 1.13 (0.92~1.39) | 0.24    |
| LAESd, mm      | 1.17 (0.95~1.43) | 0.135   |
| RAESd, mm      | 1.05 (0.89~1.23) | 0.57    |
| LVEF           | 0.88 (0.75~1.04) | 0.136   |
| PR interval    | 0.98 (0.95~1.01)  | 0.258   |
| Corrected QT interval | 1 (0.98~1.02)  | 0.916   |
| QRS duration   | 1.04 (1~1.07)   | 0.032   |

relatively low compared to that in Western countries; 23 patients in the MACE group received treatment, and 13 patients received glucocorticoids. A recent study (20) showed that the dose of corticosteroids is negatively correlated with the mortality of patients with PD-1 inhibitor-mediated myocarditis. However, these results increase the possibility that myocardial injury can be mitigated by early and intensive corticosteroid therapy. Nevertheless, the decision of whether to administer high-dose corticosteroids during clinical practice still requires consideration of various other aspects, especially infection. Certainly, we cannot rule out that this mortality rate is related to the conservative use of corticosteroid therapy. Despite the high mortality rate, we still need to risk stratify patients. We also used a logistic model to evaluate the relationship between various cardiac parameters and cardiogenic death. CK-MB, hsTNT, NT-proBNP, and QRS duration were statistically significant in predicting cardiogenic death in the MACE group. Using ROC curves for mutual comparison, hsTNT was the best marker for predicting cardiogenic death in the MACE group patients.

In 2018, the American Society for Clinical Oncology (ASCO) issued the clinical practice guidelines (21, 22) for cardiotoxicity related to ICIs. Based on this guideline, cardiotoxicity is divided into four levels according to severity (23). Patients who exhibit only increased levels of markers of myocardial injury without any symptoms are divided into 1 level and do not need corticosteroid treatment, however, monitoring of cardiac parameters needs to be continued. The results of this study may help clinicians identify, early in the course of the disease, which patients with level 1 will continue to develop symptoms and which patients with symptoms will continue to progress to death. In view of the very high mortality rate of PD-1 inhibitor-related myocarditis, these results may help us to stay aware of specific patients and provide more appropriate treatments in the early stages of disease deterioration.

This study also has some limitations. First of all, this is a single-center retrospective study. Although we want to clarify the specific probability of myocardial injury after PD-1 inhibitor treatment, a large proportion of the data is incomplete,
FIGURE 3  
(A) Receiver operating characteristic (ROC) was used to compare the accuracy of various indicators to predict the occurrence of major adverse cardiac events (MACE)  
(B) ROC curve shows that high-sensitivity troponin T (hsTNT) is the most accurate marker for predicting cardiogenic death in the MACE group.

and there are many deviations. Laboratory indicators and ECG indicators are complete, but there are missing data on cardiac ultrasound. Thus, we used the mean instead. This led to a shift in the research results. Second, we cannot completely rule out myocardial damage caused by other drugs, such as chemotherapy drugs, such as paclitaxel and platinum, although these drugs are rarely reported to cause myocardial damage, at the same time, we cannot completely rule out myocardial infarction, stress cardiomyopathy, and other causes of myocardial injury in these patients because of the lack of very complete clinical examination results. Third, the small sample size and information bias may affect the results of our study. Further research should be conducted with larger sample size and minimize the information bias for more reliable results.

Conclusion

In patients with myocardial injury after PD-1 inhibitor treatment, NT-proBNP is the superior parameter of choice to predict the likelihood of developing cardiovascular symptoms, whereas, in symptomatic patients, hSTnT is superior to other cardiac parameters and is associated with the development of death.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Human Research Committee of the Second Xiangya Hospital of Central South University. The patients/participants provided their written informed consent to participate in this study.

Author contributions

JL designed this study and performed quality control of data authenticity. XP drafted the manuscript and collected and analyzed the data. ZZ, NL, SZ, YZ, and JL revised the paper. All authors approved the final version.

Funding

This research was supported by the National Natural Science Foundation of China (82100314).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifar M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. (2020) 396:1204–22. doi: 10.1016/S0140-6736(20)30925-9

2. Zaha VG, Meijers WC, Moslehi J. Cardio-immuno-oncology. Circulation. (2020) 141:87–9. doi: 10.1161/CIRCULATIONAHA.119.042276

3. Dall’Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, et al. Tumour burden and efficacy of immune checkpoint inhibitors. Nat Rev Clin Oncol. (2021) 19:75–9. doi: 10.1038/s41571-021-00564-3

4. Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Deterbeck FC, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO Guideline. J Clin Oncol. (2020) 38:753–66. doi: 10.1200/JCO.19.02748

5. Siddiqui AZ, Almhanna K. Beyond Chemotherapy, PD-1, and HER-2: novel targets for gastric and esophageal cancer. Cancers. (2021) 13:4322. doi: 10.3390/cancers13174322

6. Kondapalli I, Neilan TG. Immune checkpoint inhibitors and cardiovascular events among patients with cancer: a window into the critical role of the immune system in cardiovascular biology. Eur Heart J. (2021) 42:4978–80. doi: 10.1093/eurheartj/ehab708

7. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. (2016) 60:210–25. doi: 10.1016/j.ejca.2016.02.024

8. Johnson DB, Ballo JM, Compton ML, Chalkias S, Cottrill SA, Farb A, et al. Fulminant myocarditis with combination immune checkpoint blockade. New England J Med. (2016) 375:1749–55. doi: 10.1056/NEJMoa1609214

9. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. (1997) 277:925–6. doi: 10.1001/jama.277.11.925

10. Hicks KA, Iuchnur RE, Bozkurt B, Chatman BR, Cutlip DE, Farb A, et al. ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American college of cardiology/American heart association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). Circulation. (2015) 132:902–61. doi: 10.1161/CIR.0000000000000116

11. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohn M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2021) 42:3599–726. doi: 10.1093/eurheartj/ehab688

12. Stein-Merlo AF, Rolfberg MV, Ribas A, Yang EH. Cardiotoxicities of novel cancer immunotherapies. Heart. (2020) 107:1694–1703. doi: 10.1136/heartjnl-2021-318083

13. Mahmood SS, Bradly MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM et al. myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. (2018) 71:1755–64. doi: 10.1016/j.jacc.2018.02.037

14. Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steinberg RM, Gregory W, et al. myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist. (2018) 23:874–8. doi: 10.1634/theoncologist.2018-01357

15. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon D, Dada R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of Cancer (STIC) toxicity management working group. J Immunother Cancer. (2017) 5:95. doi: 10.1186/s40425-017-0303-0

16. Zlotof DA, Hassan M, Zafar A, Alvi RM, Awadalla M, Mahmood SS, et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. (2021) 9:e002553. doi: 10.1159/jtc.2021-002553

17. Rubio-Infante N, Ramirez-Flores YA, Castillo EC, Lotan O, Garcia-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. (2021) 23:1793–47. doi: 10.1002/ejhf.2289

18. Puzanov I, Subramanian P, Yatsynovich YV, Jacobs DM, Chilbert MR, Sharma UC, et al. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. (2021) 9:e002553. doi: 10.1159/jtc.2021-002553

19. Pathak R, Katif A, Massarelli E, Villafior V, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myocarditis/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. (2021) 26:1052–61. doi: 10.1016/j.onco.13931

20. Zhang L, Zlotof DA, Awadalla M, Mahmood SS, Nohria A, Hassan M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. (2020) 141:2031–4. doi: 10.1161/CIRCULATIONAHA.119.044703

21. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. (2021) 39:4073–4126. doi: 10.1200/JCO.21.01440

22. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brussel KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. (2018) 36:16714–68. doi: 10.1200/jco.2017.77.6385

23. Lyon AR, Dent S, Stanway S, Earl H, Breden-Massey C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiac-oncology cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the european society of cardiology in collaboration with the international cardio-oncology society. Eur J Heart Fail. (2020) 22:1945–60. doi: 10.1002/ejhf.1920